Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $41.20 Consensus Target Price from Analysts
Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX – Get Free Report) have been assigned a consensus rating of “Buy” from the eight brokerages that are currently covering the firm, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average […]
Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX – Get Free Report) have been assigned a consensus rating of “Buy” from the eight brokerages that are currently covering the firm, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average […]
